WO2026067520 - ANTI-CLL-1 NANOBODY AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/067520
Publication Date
02.04.2026
International Application No.
PCT/CN2025/123920
International Filing Date
25.09.2025
Title **
[English]
ANTI-CLL-1 NANOBODY AND USE THEREOF
[French]
NANOCORPS ANTI-CLL-1 ET SON UTILISATION
[Chinese]
抗CLL-1的纳米抗体及其应用
Applicants **
HANGZHOU BIO-SINCERITY PHARMA-TECH CO., LTD.
Inventors
ZHU, Ziyan
BU, Ruihong
DING, Ming
TIAN, Meng
YANG, Yang
DANG, Yunqi
REN, Jie
WEN, Mengzhao
CHENG, Lu
CHEN, Jialu
WEN, Qingxia
CHEN, Jingchun
XU, Yan
WANG, Jianghai
MIAO, Lei
LOU, Jinfang
Priority Data
202411351532.X
26.09.2024
CN
202510548738.X
28.04.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2297 | |
| EPO | Filing, Examination, Granting | 16795 | |
| Japan | Filing, Examination, Granting | 2400 | |
| South Korea | Filing, Examination, Granting | 2695 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
29,527
Contact Us
Abstract[English]
Provided are an antibody or an antigen-binding fragment thereof that specifically binds to CLL-1, a multispecific antigen-binding molecule, a chimeric antigen receptor, an immune effector cell, a nucleic acid fragment, a vector, a host cell, a pharmaceutical composition, a kit, a preparation method, and the use thereof in treating diseases and detecting CLL-1.[French]
L'invention concerne un anticorps ou un fragment de liaison à l'antigène de celui-ci qui se lie spécifiquement à CLL-1, une molécule multispécifique de liaison à l'antigène, un récepteur antigénique chimérique, une cellule effectrice immunitaire, un fragment d'acide nucléique, un vecteur, une cellule hôte, une composition pharmaceutique, un kit, un procédé de préparation et leur utilisation dans le traitement de maladies et la détection de CLL-1.[Chinese]
提供了一种特异性结合CLL-1的抗体或其抗原结合片段、多特异性抗原结合分子、嵌合抗原受体、免疫效应细胞、核酸片段、载体、宿主细胞、药物组合物、试剂盒、制备方法及其在治疗疾病以及检测CLL-1中的应用。